Chief Commercial Officer
Brandt Charters is a commercial leader with more than 30 years of experience building and growing sales teams and commercial organizations that are focused on improving patients’ lives. Brandt nurtures a culture of customer-centered, scientifically driven advancements to bringing emerging technologies into the healthcare space. His career has encompassed a variety of life science focused companies – pharmaceuticals, medical device, SAAS, and over 20 years of diagnostics.
Brandt brings valuable start-up experience and has developed his skills from the ground up. He started his career as a field rep with Syntex labs, and then entered the Neurology space as part of the inaugural Athena Neurosciences sales team. He earned increased responsibilities as National Trainer, Regional Sales Manager before becoming the National Sales Manager where he hired and led the Athena/Elan sales organization before entering the diagnostics space.
He has been involved with the initiation and growth of several diagnostics companies such as Athena Diagnostics, and established the US/North American sales organizations for both GeneDx, and Blueprint Genetics. He has built and led teams consisting of sales, marketing, billing, managed markets, business development and pharma/biopharma partnerships.
Brandt believes that a strong patient focus is important and strives to work with patient facing organizations. His family experiences with both AD and LBD makes the mission at Amprion one that is very close to home and personal.
Amprion has some important news we need to share with you!
To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.
Old self-pay price: $1500.00. New self-pay price: $995.00
Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process